Table I.
Reversal activity of six uncaria alkaloids in HepG2/ADM cells and their parental cells.
| Treatments | IC50 ± SDa (μM) (fold-reversalb)
|
|
|---|---|---|
| HepG2/ADM | HepG2 | |
| DOX | 78.5314±9.7768 (1.00) | 0.3357±0.0193 (1.00) |
| + Rhy 50 μM | 5.4859±2.7101 (14.32) | 0.3852±0.1186 (0.87) |
| + Irhy 50 μM | 3.9646±1.1056 (19.81) | 0.3678±0.0261 (0.91) |
| + Cory 50 μM | 5.2865±0.7767 (14.86) | 0.3278±0.1221 (1.02) |
| + Icory 50 μM | 2.5256±0.6897 (31.09) | 0.3653±0.0849 (0.92) |
| + HS 3 μM | 15.2977±0.7666 (5.13) | 0.3982±0.0796 (0.84) |
| + HST 3 μM | 14.3615±2.0456 (5.47) | 0.4124±0.0153 (0.81) |
a
Data in the table are shown as means ± SD of three independent experiments performed in six replicates.
b
The fold-reversals are calculated as IC50 for cells with the anticancer drug in the absence of inhibitors divided by that in the presence of inhibitors.